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Neurologic complications caused by spinal cord
ischemia constitute a significant risk in thoracoab-
dominal aortic surgery. Numerous strategies for
decreasing the risk of neurologic deficits, both sur-
gical and pharmacological, have been examined.1,2
Pharmacological agents, such as the vasodilator
papaverine3 and the opioid antagonist naloxone,4
aim to increase the ischemic tolerance of the spinal
cord. Many other pharmacological agents, including
free radical scavengers, L-type calcium channel
blockers, magnesium, barbiturates, corticosteroids
and N-methyl-D-aspartate antagonists, have been
tested in animal models of spinal ischemia.1,2
Despite the advantage afforded by preemptive med-
ication, no pharmacological agent has consistently
demonstrated profound neuroprotection in animal
models of spinal ischemia or in clinical trials of
patients with aortic aneurysms. The strategy of deep
regional hypothermia induced intrathecally has
achieved complete neuroprotection in animal mod-
els,5-7 and moderate hypothermia with epidural
cooling has been reported to reduce the incidence of
spinal cord complications clinically.8 Some have sug-
gested combining pharmacological agents with
epidural cooling.9,10
The current study examined the neuroprotective
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Purpose: Spinal cord ischemia and resulting paraplegia represent a major complication
associated with surgical repair of the thoracoabdominal aorta. Although the mechanism
of spinal neuronal degeneration during ischemia is unclear, it may involve excessive cal-
cium influx via N-type voltage-sensitive calcium channels (VSCCs). The neuroprotective
capacity of intrathecal (IT) administration of the selective N-type VSCC blocker
ziconotide, previously shown to be potently analgesic, was studied.
Methods: In a rat aortic occlusion model, spinal cord ischemia was induced for 8, 9, or
10 minutes by occluding the descending thoracic aorta. Ziconotide was administered IT
as (1) a continuous infusion of 300 or 600 ng/kg/h initiated 24 hours before ischemia
and continuing an additional 24 hours or (2) a 0.3 m g bolus injected 45 minutes before
the induction of ischemia. Animals were allowed to live for 24 hours, and recovery of
motor function was evaluated during this period. Spinal cords were processed using a
silver impregnation technique and microtubule-associated protein type II (MAP2)
immunohistochemistry.
Results: Continuous IT infusion of ziconotide provided significant protection against 8-
and 9-minute occlusions, but not 10-minute occlusions, as indicated by recovery of
motor function, degree of spinal neuronal degeneration, and loss of MAP2 immunore-
activity. Acute IT pretreatment with ziconotide provided transient protection during the
initial 4 hours of reperfusion; however, this protective effect was no longer present at
24 hours.
Conclusion: These data implicate N-type VSCC activation in spinal neuronal degenera-
tion caused by transient spinal ischemia, because selective blockade of this channel by
continuous IT infusion of ziconotide was protective against injurious intervals of spinal
ischemia. Based on these findings, ziconotide may provide both neuroprotection and
preemptive analgesia for aortic aneurysm surgery. (J Vasc Surg 1999;30:334-43.)
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capacity of ziconotide (SNX-111), a selective block-
er of neuronal N-type voltage-sensitive calcium
channels (VSCCs), in a rat model of transient spinal
ischemia. Ziconotide was first tested against the least
severe ischemic interval that consistently produced
spinal damage. In an attempt to maximize the dura-
tion of action and thus the potential neuroprotec-
tion by ziconotide, the first study used a continuous
intrathecal (IT) infusion beginning 24 hours before
the ischemic insult and continuing through a reper-
fusion period of 24 hours. After establishing doses
by means of continuous IT infusion that reduced
neuronal damage after ischemic intervals of increas-
ing severity, we examined whether an acute IT bolus
of ziconotide administered before the induction of
ischemia would also provide neuroprotection. If
effective, an acute bolus delivered just before aortic
aneurysm surgery may be preferred clinically.
Ziconotide has previously been shown to be neu-
roprotective in animal models of both focal11 and
global12 cerebral ischemia. The mechanism of neu-
roprotection by ziconotide in cerebral ischemia is
thought to be caused by the prevention of excessive
calcium flux into neurons.13 N-type VSCCs are
widespread in the brain. In the spinal cord, they are
highly concentrated in the dorsal horn but are also
detectable by means of immunohistochemistry on
ventral horn motor neurons and surrounding neu-
ropil.14,15
MATERIALS AND METHODS
Animals. Seventy-two male Sprague-Dawley
rats, weighing 290 to 340 grams, were used. Animals
were housed in individual cages, allowed free access
to food and water, and kept on a 12-hour light/dark
cycle in a facility maintained at 20˚C to 23˚C. All
experiments were carried out with the approval of the
Institutional Animal Care and Use Committee.
Implantation of intrathecal catheters and
minipumps. The rats were implanted with indwelling
IT catheters, as described by LoPachin.16 In brief, rats
were anesthetized (2% halothane carried by 30% oxy-
gen and 70% nitrous oxide), and a narrow-gauge,
saline-filled polyethylene (PE-10) tube was inserted
into the cisterna magna and carefully advanced to the
lumbar enlargement of the spinal cord. The external
end of the catheter was anchored to the cervical mus-
culature before closing the incision. Animals receiving
continuous infusions were implanted with catheters
with the external ends fused by heat to PE-60 tubing
to allow connection with osmotic minipumps. Animals
showing signs of motor impairment after catheter
insertion (approximately 5% to 10%) were excluded
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from experiments. The rats were allowed a 3- to 5-day
recovery period after catheterization.
IT bolus injections were delivered in a volume of
10 m L, followed by 10 m L saline to flush the
catheter. For continuous IT infusions, rats were
anesthetized as before, and the catheters were con-
nected to osmotic minipumps (Alzet Model 1003D,
Alza Corporation, Palo Alto, Calif) filled with saline
or ziconotide. The pumps infused solutions at a con-
stant rate of 1 m L/h continuously for 3 days. Once
connected to the catheter, the pumps were implant-
ed subcutaneously above the scapula.
Induction of spinal ischemia. This rat model
of transient aortic occlusion uses an external reser-
voir to allow partial exsanguination via the carotid
artery during the occlusion, which alleviates proxi-
mal hypertension, creating a more consistent and
profound ischemia to the lumbar spinal cord.17 The
blood withdrawn was held at 37.4˚C in a heating
coil (Radnoti Glass, Monrovia, Calif) and replaced
immediately after the occlusion.
Animals were anesthetized (2% halothane carried
by 30% oxygen and 70% nitrous oxide) during the
entire procedure. Rectal temperature was monitored
and maintained at 36.8˚C to 37.8˚C by means of a
homothermic blanket system (Harvard Apparatus,
South Natick, Mass) and, when necessary, a heating
pad. Distal blood pressure (distal to the heart from
the occlusion) was monitored via a tail artery catheter
(PE-50) connected to a blood pressure transducer
(MacLab, ADInstruments, Milford, Mass).
Before the occlusion, a 20-gauge catheter was
placed in the carotid artery, connected with
polyurethane tubing to the heating coil and con-
nected at the other end with polyurethane tubing to
an inverted 60-mL open syringe. The entire assem-
bly was filled with heparinized saline (3 U/mL) to
the mouth of the inverted syringe, which was posi-
tioned 54 cm above the rat to maintain proximal
blood pressure at 40 mm Hg during the occlusion.
To induce spinal ischemia, the thoracic aorta was
occluded with a Fogherty arterial embolectomy
catheter (Model 120602F; Baxter, Santa Ana, Calif)
inserted into the aorta via the femoral artery to a dis-
tance of 10 cm from the incision. Immediately after
inflating the catheter, the heating coil was opened via
a three-way stopcock at the mouth of the syringe,
allowing collection of blood. After 8, 9, or 10 min-
utes, the catheter was deflated, and the blood given
back by forcing a volume of saline equivalent to that
displaced by the blood back into the heating coil.
Immediately after reperfusion, before removing the
catheters, the animal was given 0.4 mL protamine sul-
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fate (25 mg/mL solution) to counteract the heparin.
When the temperature and blood pressure were
restored to baseline levels, the animal was allowed to
recover.
Evaluation of motor function. Motor function
was assessed 1, 2, 4, and 24 hours after reperfusion.
The motor score was the sum of separate ratings for
walking (0 to 4) and stepping (0 to 2). Walking with
lower extremities was graded as: 0, normal; 1, toes
flat under body when walking, but with ataxia; 2,
knuckle walking; 3, movement of hindlimbs, but
inability to knuckle walk; and 4, no movement, drags
lower extremities. The stepping reflex was rated as: 0,
normal; 1, weak; and 2, no stepping.
Histology. The animals were killed with an
overdose of pentobarbital and perfused transcardial-
ly with 0.9% saline (2 units heparin/mL), followed
by 4% paraformaldehyde (PFA). The vertebral col-
umn (T12 to L2) was removed and postfixed whole
in 4% PFA overnight at 4˚C, before removing the
lumbar enlargement of the spinal cord. After wash-
ing in 0.1 mol/L phosphate buffer, the cord was
stored in 20% sucrose in 0.1 mol/L phosphate
buffer at 4˚C for 1 to 3 days before fast freezing with
isopentane and cryostat sectioning. Transverse sec-
tions (30 m m) were cut, and two series of every sev-
enth section were collected for silver-staining and
immunohistochemistry for microtubule-associated
protein type II (MAP2).
To visualize dying neurons, spinal cord sections
stored at 4˚C in 4% PFA were stained with the FD
NeuroSilver Kit I (FD NeuroTechnologies, Ellicott
City, Md). The silver-stained sections from each ani-
mal were evaluated, and neuronal damage was rated
from 1 to 5, according to this scale: 1, less than 5%
of neurons affected; 2, less than 10% of neurons
affected; 3, less than 50% of neurons affected; 4, 50%
or more of neurons affected; 5, 75% or more of neu-
rons affected, including some alpha motor neurons.
For MAP2 immunohistochemistry, spinal cord
sections were stored in PBS at 4˚C. The procedure
used a monoclonal mouse anti-MAP2 primary anti-
body (Zymed, South San Francisco, Calif), a goat
anti-mouse biotinylated secondary antibody, a strep-
tavidin-enzyme conjugate (Zymed), and diaminoben-
zidine chromogen.
MAP2 staining was quantified with image analysis
software (Q500MC, Leica Cambridge, Cambridge,
UK) by measuring the area of gray matter that stained
the same intensity of brown as the gray matter in non-
ischemic control spinal cord sections. Areas of lighter
staining, reflecting neuronal damage or loss, were not
included in this area measurement, which was record-
ed in thousands of pixels. An average value for the
area of MAP2 staining that matched the non-ischemic
control intensity of MAP2 was calculated for each ani-
mal from right and left sides of five to eight spinal
cord sections.
Statistics. The behavioral data were analyzed by
two-way analysis of variance (ANOVA). Group dif-
ferences and individual time points were analyzed by
post hoc t tests. Group differences in MAP2 staining
were assessed by two-way ANOVA, and comparisons
of neuronal damage in silver-stained sections were
analyzed by t tests.
Experimental designs. Table I summarizes
experimental designs for separate experiments,
investigating the effects of continuous IT infusions
or a single IT bolus of ziconotide.
RESULTS
Fig 1 shows representative lumbar spinal cord
sections from animals that received continuous IT
infusions of ziconotide or saline that were processed
using MAP2 immunohistochemistry. Compared
with MAP2 staining in the lumbar spinal cord of a
control, non-ischemic animal, MAP2 staining was
reduced in spinal cord sections from animals under-
Table I. Summary of experiments designed to investigate the effects of continuous intrathecal infusion or
an intrathecal bolus dose of ziconotide on spinal ischemic damage
Experiment Groups Ziconotide dose Timing of dose Ischemic interval
I Saline: n = 8 300 ng/kg/h continuous IT infusion 24 hours preocclusion until 24 hours after 8 minutes
Ziconotide: n = 8
II Saline: n = 16 300 or 600 ng/kg/h continuous IT 24 hours preocclusion until 24 hours after 9 minutes
Ziconotide: n = 8 infusion
III Saline: n = 8 600 ng/kg/h continuous IT infusion 24 hours preocclusion until 24 hours after 10 minutes
Ziconotide: n = 8
IV Saline: n = 8 300 ng IT bolus 30 to 45 minutes preocclusion 9 minutes
Ziconotide: n = 8
IT, intrathecal.
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going 8-, 9-, and 10-minute aortic occlusions.
Continuous IT ziconotide infusions of 300
ng/kg/h and 600 ng/kg/h preserved MAP2 stain-
ing in spinal cord sections from animals undergoing
8- and 9-minute aortic occlusions, respectively, but
600 ng/kg/h ziconotide did not prevent the loss of
MAP2 staining in animals undergoing 10-minute
aortic occlusions. Fig 2 shows examples of silver-
stained sections corresponding to 1, 3, and 5 on 
the rating scale. Quantification of the effects of
ziconotide on MAP2 immunohistochemistry, silver-
staining, and motor function in experiments I to IV
are shown below.
In addition to silver-staining and MAP2 immuno-
chemistry, sections from some animals were TUNEL
(TdT-mediated dUTP Nick-End Labeling) stained,
revealing that a large number of neurons were dying
by apoptosis (data not shown). Although many
Fig 1. Microtubule-associated protein type II (MAP2) staining of lumbar spinal sections in a
control animal (A) and animals receiving aortic occlusions of 8 minutes (B and C), 9 minutes
(D and E), and 10 minutes (F and G). Sections from saline-treated animals are shown in B,
D, and F. A section from an animal receiving 300 ng/kg/h ziconotide is shown in C, and E
and G show spinal cord sections from animals receiving 600 ng/kg/h ziconotide. Note the
lighter staining in panels B, D, and F and the preservation of MAP2 staining by ziconotide
after 8- and 9-minute aortic occlusions (C and E, respectively; original magnification, 100· ).
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TUNEL-positive cells were found in animals killed at
24 hours, the strongest TUNEL staining was seen in
the spinal cords from animals killed 4 hours after
ischemia.
Experiment I: 8-minute occlusions. Osmotic
minipumps delivering continuous IT infusions of 300
ng/kg/h ziconotide or saline were started 24 hours
before an 8-minute aortic occlusion and lasted until
the animals were killed 24 hours postocclusion.
Ziconotide-treated animals had less severe motor
impairments and spinal cord damage than saline-
treated control animals. Significant main effects of
treatment (P < .0001) and time (P = .0001) on motor
scores and no interaction were shown by the two-way
ANOVA, indicating a clear effect of ziconotide.
Motor scores for saline and ziconotide-treated rats
were 4.9 ± 0.2 and 2.7 ± 0.3 at 1 hour, 4.7 ± 0.2 and
2.1 ± 0.4 at 2 hours, 4.6 ± 0.3 and 1.8 ± 0.4 at 4
Fig 2. Silver-stained lumbar spinal cord sections illustrating the range of damage and the cor-
responding rating scale for spinal neuronal damage in animals in these experiments. A and B,
A typical section with a rating of 1 (less than 5% damage). Note that silver-stained neurons are
restricted to the dorsal horn. C and D, A typical section with a rating of 3 (less than 50% dam-
age). This level of damage includes cells in the intermediate zone. E and F, An example of neu-
ronal damage rated as 5 (75% or more damage). Note the area of cell loss in the intermediate
zone and the silver-staining of a ventral horn alpha motor neuron (Original magnification of
A, C, and E, 100· ; original magnification of B, D, and F, 160· ).
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hours, and 3.2 ± 0.7 and 0.7 ± 0.3 at 24 hours,
respectively. Differences in motor scores at individual
time points were significant (P < .01 for 24 hours, and
P < .0001 for all other time points).
Silver-staining ratings revealed an overall differ-
ence in neuronal damage between groups (saline,
2.7 ± 0.4; ziconotide, 1.7 ± 0.3; P < .05). A signif-
icant effect of ziconotide treatment was revealed by
analyses of MAP2 immunohistochemistry (P <
.01); significant differences (P < .05) in the area of
MAP2 staining at spinal levels L3 to L4 (saline:
39.7 ± 6.0, ziconotide: 66.4 ± 10.8) and L4 to L5
Fig 3. Protective effect of continuous intrathecal infusion of 600 ng/kg/h ziconotide vs.
saline or 300 ng/kg/h ziconotide started 24 hours before a 9-minute aortic occlusion. 
A, Motor behavior (P < .0001 for 600 ng/kg/h). B, Neuronal damage indicated by silver-
staining ratings of lumbar spinal cord (P < .001 for 600 ng/kg/h). C, Microtubule-associat-
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(saline: 38.6 ± 8.2, ziconotide: 65.6 ± 6.8) were
revealed by t tests of separate thirds of the lumbar
enlargement.
Experiment II: 9-minute occlusions. Osmotic
minipumps delivering continuous IT infusions of
either 300 or 600 ng/kg/h ziconotide or saline were
started 24 hours before a 9-minute aortic occlusion
and continued until the animals were killed 24 hours
after the occlusion. Although the 300 ng/kg/h dose
was not neuroprotective for this ischemic interval,
600 ng/kg/h ziconotide provided significant neuro-
protection, as seen by a main effect of this dose on
motor behavior (Fig 3A; P < .0001; two-way
ANOVA). A significant treatment effect only for the
600 ng/kg/h group was revealed by separate
ANOVAs of the low- and high-dose groups (P <
.0001).
Consistent with the behavioral data, only the
animals treated with 600 ng/kg/h ziconotide sus-
tained significantly less neuronal damage than saline-
treated animals, visualized by silver-staining (Fig 3B;
treatment effect P < .001; P < .001 with post hoc
analysis). Similarly, separate ANOVAs of MAP2
immunostaining of the low-dose (300 ng/kg/h)
and high-dose (600 ng/kg/h) groups revealed no
significant difference between low-dose ziconotide
and saline-treated animals, but a significant differ-
ence between high-dose and saline-treated animals
(Fig 3C, P < .0001).
This preservation of motor behavior, seen at 24
hours after reperfusion in animals given continuous
IT ziconotide infusions of 600 ng/kg/h, was stable
for at least 1 week after termination of the infusion
(separate animals; data not shown).
Experiment III: 10-minute occlusions.
Osmotic minipumps delivering continuous IT infu-
sions of 600 ng/kg/h ziconotide or saline were start-
ed 24 hours before a 10-minute aortic occlusion and
lasted until the animals were killed 24 hours after the
occlusion. There was a slight but significant preserva-
tion of motor function with ziconotide (Fig 4; P <
.001), because of differences at 2 and 4 hours (t tests;
P < .05), but not at 1 or 24 hours. There were no sig-
nificant differences in neuronal damage detected by
silver-staining or MAP2 immunostaining.
Experiment IV: Bolus injection, 9-minute
occlusion. IT bolus injections of 0.3 m g ziconotide
30 to 45 minutes before a 9-minute aortic occlusion
provided transient preservation of motor behavior.
Although there was an overall effect of ziconotide
on motor scores (Fig 5, P < .05), motor scores at 1,
2, and 4 hours revealed only trends toward signifi-
cance, and at 24 hours, they were identical. There
was no difference in spinal neuronal damage as
assessed by means of silver-staining in ziconotide
versus saline animals.
DISCUSSION
These experiments demonstrate a neuroprotec-
tive effect of ziconotide in a rat model of transient
spinal ischemia that produces damage of the kind
that can occur during aortic aneurysm repair. The
protection appears to be lasting, because animals
that survived for a week after the termination of
ziconotide treatment maintained their level of motor
function. The finding that an IT bolus of 0.3 m g
ziconotide given before a 9-minute occlusion caused
a transient preservation of motor function for the
first 4 hours suggests that a minimum concentration
of ziconotide must be maintained during a critical
Fig 4. Effect on motor behavior of continuous intrathecal infusion of 600 ng/kg/h
ziconotide vs. saline started 24 hours before a 10-minute aortic occlusion (P < .05 for time
points of 2 and 4 hours).
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period in the first 24 hours of reperfusion to achieve
lasting neuroprotection. The TUNEL-positive cells
in tissue taken at 24 hours postischemia further sug-
gest that ziconotide may need to be present during
this reperfusion period.
Although the aortic occlusion model used here
caused damage to neurons throughout the gray mat-
ter of the lumbar spinal cord, there was a clear gra-
dient of susceptibility starting in the superficial lam-
inae of the dorsal horn, progressing through the
intermediate zone, and terminating in the alpha
motor neurons of the ventral horn. Animals with
damage restricted to the dorsal horn showed slight,
if any, motor impairment. Because neurons in the
dorsal horn are involved in sensory function, it is
important that these animals showed no evidence of
sensory impairments. Even animals with motor
impairments responded to sensory stimulation (a
pinch) of the hindpaws. These damaged dorsal horn
neurons represent a small percentage in an area of
high neuronal density. Animals with observable
motor impairments had additional neuronal damage
in the intermediate zone, manifested by spastic para-
plegia caused by loss of inhibition of ventral motor
neurons. Animals with the most severe motor
impairments had additional neuronal loss in the ven-
tral horn, which impinged on alpha motor neurons.
These rats also showed a spastic paraplegia, because
the number of alpha motor neurons damaged was
too few to cause flaccid paraplegia, which occurs
with longer occlusion intervals (eg, 12 minutes) in
this model.11
Although the mechanism of neuronal damage in
this setting is not fully elucidated, several possibilities
involve calcium influx. First, the increase in gluta-
mate known to occur in ischemia causes the activa-
tion of N-methyl-D-aspartate antagonists receptors
and calcium influx. Second, the activation of VSCCs
also leads to calcium influx, and it is the blockade of
this influx that is a proposed mechanism of neuro-
protection by ziconotide in models of cerebral
ischemia.12,13 Another proposed mechanism of neu-
roprotection by N-type VSCC blockade is the pre-
vention of transmitter release by presynaptic termi-
nals.18 Because N-type VSCCs in the spinal cord are
found in highest density in the dorsal horn14,15 and
are concentrated there on afferent terminals,15,19 it is
likely that the neuroprotection of spinal neurons by
ziconotide in this model may be largely presynaptic.
A presynaptic blockade of neurotransmitter
release may be quite neuroprotective in spinal
ischemia, because the dorsal horn neurons that are
most susceptible in this model may also be hyperex-
citable under ischemic stress. Neurons in the dorsal
horn have been shown to be hyperexcitable during
spinal ischemia and reperfusion,20 as well as during
neuropathic pain21 and possibly during neurogenic
inflammation.22 Single unit recordings have shown
the hyperexcitability of dorsal horn neurons during
an inflammatory pain state to be attenuated by N-
type VSCC blockade.23 Thus, it is possible that
blockade of N-type VSCCs in the dorsal horn could
provide widespread protection of spinal neurons
against ischemia by preventing a transsynaptic depo-
larization cascade. Furthermore, blocking release of
diffusible peptides by afferent terminals in the dorsal
horn could also impact the survival of more distant
neurons under ischemic stress.
Indirect evidence of neuronal hyperexcitability in
the spinal cord has been obtained in a clinical study
Fig 5. Effect on motor behavior of a single intrathecal bolus of 0.3 m g ziconotide vs. saline
delivered 30 to 45 minutes before a 9-minute aortic occlusion (P < .05 for treatment effect in
two-way analysis of variance; individual time points not significant).
that showed that increased cerebrospinal fluid levels
of glutamate and aspartate are associated with neu-
rologic deficits after thoracoabdominal aneurysm
repair.24 Because synaptic transmission between dor-
sal root ganglion cells and spinal neurons in vitro can
be presynaptically inhibited by N-type VSCC block-
ade,19 it is possible that ziconotide protects against
spinal ischemic injury by suppressing ischemia-
induced hyperexcitability of dorsal horn neurons.
In conclusion, the present results demonstrate
that IT administration of the N-type VSCC blocker
ziconotide protects spinal neurons from ischemic
damage in a rat model of transient spinal ischemia.
Because ziconotide has potent analgesic properties
when administered IT25,26 and is currently in clinical
trials for postsurgical pain, the use of this compound
in thoracoabdominal aortic aneurysm surgery may
serve a dual purpose: postoperative pain management
and neuroprotection of spinal cord. In addition, it
may be beneficial in avoiding the use of epidural opi-
ate analgesia, which has been reported anecdotally to
cause a transient paraplegia after aortic aneurysm
repair (Kenneth Davison, personal communication)
and after noninjurious ischemic intervals in this rat
model.27 These effects are reversed by the opiate
antagonist naloxone. Although naloxone has been
reported to provide some degree of permanent pro-
tection from spinal ischemia,4 it is unclear whether
epidural narcotics might actually increase the risk of
permanent neurologic deficit after this surgery.
Permanent neuronal damage has occurred in this rat
model when three doses of intrathecal morphine
were given in the first 24 hours after a noninjurious
ischemic interval of 6 minutes (Martin Marsala, per-
sonal communication). Thus, ziconotide might serve
as a non-opiate alternative for postsurgical pain man-
agement, while providing spinal cord neuroprotec-
tion for aortic aneurysm repair.
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